Mega Pharmaceuticals limited
Public pharmaceutical manufacturer · Lahore · Pakistan
Lahore pharmaceutical manufacturer producing general and cephalosporin medicines and marketing a broad branded-generic portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical manufacturer
- Website
- megapharma.com.pk ↗
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 63%
Company location
No exact premises location is published without a defensible source.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Macromax | Azithromycin | 250 mg | Capsule | 1 x 6's | 032671 | PKR 249.34 | PKR 41.56/capsule | 16% below median |
| Macromax | Azithromycin | 250 mg | Capsule | 1 x 10's | 032671 | PKR 394.95 | PKR 39.50/capsule | 20% below median |
| MacromaxSource observed | Azithromycin | 200 mg/5 mL | Held for normalizationSource reported: Capsule · structural field conflict | 15 mL | 068055Official source ↗ | No indexed price | — | — |
| Macromax | Azithromycin | 250 mg | Tablet | 6's | 105744 | PKR 276.99 | PKR 46.17/tablet | Near median |
| Macromax | Azithromycin | 500 mg | Tablet | 6's | 105745 | PKR 507.81 | PKR 84.64/tablet | Near median |
| Macromax Susp. 200 mg/5 mL Each 5ml Contains (Azithromycin as Dihydrate..200mg)Source observed | — | — | — | 15 mL | 068055Official source ↗ | No indexed price | — | — |
| Mega HCQ | Hydroxychloroquine | 200 mg | Tablet | 50's | 106095 | PKR 830.96 | PKR 16.62/tablet | 15% above median |
| Mega HCQ | Hydroxychloroquine | 200 mg | Tablet | 30's | 106095 | PKR 498.58 | PKR 16.62/tablet | 15% above median |
| Mega Mether | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 080888 | PKR 638.30 | PKR 39.89/tablet | Near median |
| Mega Mether 40/240 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 10's | 080887 | PKR 638.55 | PKR 63.86/tablet | Near median |
| Mega-C | Ascorbic acid | 500 mg | Chewable tablet | 40's | 106096 | PKR 63.68 | PKR 1.59/tablet | 20% above median |
| Megadip | Amlodipine | 5 mg | Tablet | 25 x 20's | 032876 | PKR 4,422.42 | PKR 8.84/tablet | 18% below median |
| Megadip | Amlodipine | 5 mg | Tablet | 1 x 20's | 032876 | PKR 209.44 | PKR 10.47/tablet | Near median |
| Megadip | Amlodipine | 5 mg | Tablet | 2 x 10's | 032876 | PKR 209.44 | PKR 10.47/tablet | Near median |
| Megadip | Amlodipine | 10 mg | Tablet | 25 x 20's | 032877 | PKR 8,219.99 | PKR 16.44/tablet | 7% below median |
| Megadip | Amlodipine | 10 mg | Tablet | 2 x 10's | 032877 | PKR 389.31 | PKR 19.47/tablet | 14% above median |
| Megafast | Fexofenadine | 120 mg | Tablet | 10 x 10's | 032880 | PKR 2,598.37 | PKR 25.98/tablet | Near median |
| Megafast | Fexofenadine | 120 mg | Tablet | 1 x 10's | 032880 | PKR 282.48 | PKR 28.25/tablet | 10% above median |
| Megafast | Fexofenadine | 180 mg | Tablet | 10 x 10's | 032881 | PKR 3,360.59 | PKR 33.61/tablet | Near median |
| Megafast | Fexofenadine | 180 mg | Tablet | 1 x 10's | 032881 | PKR 365.28 | PKR 36.53/tablet | 12% above median |
| Megafast | Fexofenadine | 60 mg | Tablet | 10 x 10's | 035220 | PKR 1,217.61 | PKR 12.18/tablet | Near median |
| Megafast | Fexofenadine | 60 mg | Tablet | 1 x 10's | 035220 | PKR 133.94 | PKR 13.39/tablet | 10% above median |
| Megalid | Linezolid | 600 mg | Tablet | 12's | 103401 | PKR 4,719.87 | PKR 393.32/tablet | Near median |
| Megalid | Linezolid | 400 mg | Tablet | 12's | 103402 | PKR 2,696.01 | PKR 224.67/tablet | Near median |
| Megalid | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 103403 | PKR 646.30 | PKR 10.77/mL | Near median |
| Megalor | Loratadine | 10 mg | Tablet | 25 x 20's | 032867 | PKR 6,974.73 | PKR 13.95/tablet | Near median |
| Megalor | Loratadine | 10 mg | Tablet | 1 x 10's | 032867 | PKR 165.16 | PKR 16.52/tablet | 15% above median |
| Megamycin | Clarithromycin | 250 mg | Tablet | 1 x 10's | 032872 | PKR 453.16 | PKR 45.32/tablet | Near median |
| Megamycin | Clarithromycin | 500 mg | Tablet | 1 x 10's | 032873 | PKR 797.88 | PKR 79.79/tablet | Near median |
| Megamycin | Clarithromycin | 125 mg/5 mL | Suspension | 60 ml | 068057 | PKR 444.82 | PKR 7.41/mL | Near median |
| Megapol | Paracetamol | 500 mg | Tablet | 500’s JP | 032887 | PKR 952.89 | — | No comparator |
| Megapol | Paracetamol | 500 mg | Tablet | 10 x 10's | 032887 | PKR 174.71 | PKR 1.75/tablet | 52% below median |
| Megapol | Paracetamol | 500 mg | Tablet | 100’s JP | 032887 | PKR 200.91 | — | No comparator |
| Megapol | Paracetamol | 500 mg | Tablet | 1000’s JP | 032887 | PKR 1,848.38 | — | No comparator |
| Megapol | Paracetamol | 500 mg | Tablet | 10x20’s BC | 032887 | PKR 762.93 | — | No comparator |
| Megapol | Paracetamol | 500 mg | Tablet | 10x50’s BC | 032887 | PKR 1,123.10 | — | No comparator |
| Megaprin | Acetylsalicylic acid (Aspirin) | 300 mg | Tablet | 3x10's | 032709 | PKR 133.31 | PKR 4.44/tablet | 33% above median |
| Megasar | Losartan | 50 mg | Tablet | 5 x 20's | 032875 | PKR 1,739.70 | PKR 17.40/tablet | 16% below median |
| Megasar | Losartan | 50 mg | Tablet | 1 x 20's | 032875 | PKR 362.44 | PKR 18.12/tablet | 13% below median |
| Megasar | Losartan | 50 mg | Tablet | 25 x 20's | 032875 | PKR 8,698.45 | PKR 17.40/tablet | 16% below median |
| Megasar | Losartan | 50 mg | Tablet | 2x10's | 032875 | PKR 411.96 | PKR 20.60/tablet | Near median |
| Megatop | Metoprolol Tartrate | 100 mg | Tablet | 3x10's | 032866 | PKR 365.28 | PKR 12.18/tablet | 8% below median |
| Megatop | Metoprolol Tartrate | 100 mg | Tablet | 25 x 10's | 032866 | PKR 2,570.90 | PKR 10.28/tablet | 28% below median |
| Megazole | Omeprazole | 20 mg | Capsule | 14's | 037847 | PKR 287.24 | PKR 20.52/capsule | Near median |
| Megazole | Omeprazole | 20 mg | Capsule | 1 x 10's | 037847 | PKR 179.96 | PKR 18.00/capsule | 9% below median |
| Megazole | Omeprazole | 20 mg | Capsule | 10 x 10's | 037847 | PKR 1,732.73 | PKR 17.33/capsule | 12% below median |
| Megazole | Omeprazole | 40 mg | Capsule | 2x7's | 083186 | PKR 498.67 | PKR 35.62/capsule | Near median |
| Megazole | Omeprazole | 40 mg | Capsule | 1 x 10's | 083186 | PKR 313.36 | PKR 31.34/capsule | 10% below median |
| Megazole | Omeprazole | 40 mg | Capsule | 10 x 10's | 083186 | PKR 3,008.35 | PKR 30.08/capsule | 13% below median |
| Megazolin Dry Powder | Cefazolin | 250 mg | Dry powder for injection | Vial | 047115 | PKR 94.75 | PKR 94.75/vial/unit | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.